Oncology Nursing News

Sub-Q Daratumumab/VRd Wins Approval in Newly Diagnosed Multiple Myeloma

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
KHON2

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of ...

"The continued expansion of DARZALEX delivered subcutaneously with ENHANZE into additional settings highlights its status as a cornerstone of therapy for multiple myeloma," said Dr. Helen Torley, ...
Cure Today

Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma

Darzalex Faspro significantly reduced disease progression risk in high-risk smoldering multiple myeloma, with a 51% reduction compared to active monitoring. The AQUILA study showed a median ...
Nasdaq

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat ...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Company AnnouncementNet sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & ...
manilatimes

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI® (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by ...